Your browser is no longer supported. Please, upgrade your browser.
JNJ Johnson & Johnson daily Stock Chart
Johnson & Johnson
IndexDJIA S&P500 P/E22.50 EPS (ttm)5.91 Insider Own0.02% Shs Outstand2.68B Perf Week-0.04%
Market Cap357.05B Forward P/E17.20 EPS next Y7.74 Insider Trans-35.52% Shs Float2.68B Perf Month-1.60%
Income16.34B PEG3.54 EPS next Q1.79 Inst Own67.90% Short Float0.51% Perf Quarter4.78%
Sales72.53B P/S4.92 EPS this Y8.30% Inst Trans-0.19% Short Ratio2.45 Perf Half Y12.67%
Book/sh26.72 P/B4.98 EPS next Y7.68% ROA11.30% Target Price137.05 Perf Year9.67%
Cash/sh4.79 P/C27.78 EPS next 5Y6.35% ROE22.90% 52W Range109.32 - 137.08 Perf YTD15.48%
Dividend3.36 P/FCF40.43 EPS past 5Y11.20% ROI17.00% 52W High-2.95% Beta0.78
Dividend %2.53% Quick Ratio1.00 Sales past 5Y2.00% Gross Margin69.40% 52W Low21.70% ATR1.51
Employees126400 Current Ratio1.30 Sales Q/Q1.90% Oper. Margin27.50% RSI (14)49.14 Volatility1.02% 1.09%
OptionableYes Debt/Eq0.48 EPS Q/Q-2.40% Profit Margin22.50% Rel Volume0.99 Prev Close134.17
ShortableYes LT Debt/Eq0.38 EarningsJul 18 BMO Payout53.80% Avg Volume5.62M Price133.04
Recom2.60 SMA200.03% SMA50-0.05% SMA2008.00% Volume5,546,752 Change-0.84%
Jul-21-17Downgrade BTIG Research Neutral → Sell $110
Jul-21-17Downgrade Alembic Global Advisors Neutral → Underweight
Jul-20-17Resumed Credit Suisse Outperform $148
Jul-05-17Reiterated Morgan Stanley Overweight $135 → $140
May-18-17Reiterated Stifel Hold $124 → $128
May-15-17Upgrade JP Morgan Neutral → Overweight
Jan-26-17Downgrade Wells Fargo Outperform → Market Perform
Jan-25-17Reiterated RBC Capital Mkts Outperform $133 → $128
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Aug-17-17 02:00PM  Remicade Is a Litmus Test for PBMs Bloomberg
10:31AM  How Safe Is Johnson & Johnson's Dividend? Motley Fool
06:23AM  In Trump CEO Council Exodus, Early Movers Stand Out
Aug-16-17 02:24PM  J&J's First California Talc-Powder Trial Is Headed to the Jury Bloomberg
01:57PM  7 members of Trump's manufacturing council left after Charlottesville before Trump disbanded it Business Insider
01:33PM  Jamie Dimon on Trump: 'It is a leader's role ... to bring people together, not tear them apart' CNBC
01:22PM  What Shareholders Should Make of the Johnson & Johnson-Cerecor Situation
01:15PM  As Trump disbanded advisory groups, this is who was in and who was out CNBC
11:55AM  India introduces price controls for knee implants Reuters
10:16AM  The Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak InvestorPlace
09:06AM  India introduces price controls for knee implants Reuters
08:21AM  [$$] Donald Trump attacks CEO 'grandstanders' as more quit panel Financial Times
Aug-15-17 07:39PM  Business leaders quit Trump panel; he hits back hard Associated Press
07:02PM  Will Any Major CEOs Join Trumps Shrinking Jobs Councils After His Latest Charlottesville Comments? Fortune
05:41PM  Trump loudly insists both sides to blame for Virginia violence Reuters
04:16PM  Yacktman Fund 2nd Quarter Commentary
03:57PM  Johnson & Johnson CEO to stay on Trump's advisory council to advocate for health care CNBC
01:33PM  South Carolina sues drug manufacturer over opioid crisis Associated Press
10:41AM  Lawsuit accuses drug manufacturer of worsening opioid crisis Associated Press
10:06AM  Catalyst (CPRX) Focused on Development of Pipeline Candidates Zacks
09:00AM  Amazon: The Devil You Know and the Devil You Dont 24/7 Wall St.
05:00AM  Whats Harder Than Making Copycat Biotech Drugs? Selling Them Bloomberg
Aug-14-17 07:48PM  3 Dividend Stocks Ideal for Retirees Motley Fool
07:07PM  Mercks CEO Isnt the First Biopharma Chief to Tangle With Trump Over Race Fortune
10:37AM  Pfizers Major Growth Drivers in 2Q17 Market Realist
10:37AM  Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern Zacks
09:47AM  Johnson & Johnson to Participate in 2017 Morgan Stanley Global Health Care Conference PR Newswire
09:20AM  Pacira Pharmaceuticals Focuses on Exparel's Label Expansion Zacks
Aug-13-17 02:03PM  Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions? Motley Fool
07:23AM  5 Dividend Stocks That Pay Out Over $8 Billion a Year Motley Fool
Aug-12-17 10:40AM  Edited Transcript of JNJ earnings conference call or presentation 18-Jul-17 12:30pm GMT Thomson Reuters StreetEvents
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
Aug-11-17 03:59PM  Pfizers Valuation after 2Q17 Earnings Market Realist
01:01PM  3 Billionaire Stocks for Retirees Motley Fool
10:27AM  More than half of women who got an abortion last year were using contraception MarketWatch
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
Aug-10-17 01:38PM  BUZZ- DJI: From hot to not Reuters
11:06AM  Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence
10:10AM  Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up Zacks
09:07AM  Celgenes Otezla Witnessed High Revenue Growth in 2Q17 Market Realist
07:37AM  How Celgenes Pomalyst Is Positioned after 2Q17 Market Realist
Aug-09-17 01:06PM  2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July Motley Fool
12:57PM  Why Achillion Pharmaceuticals Is Shooting 25% Higher Today Motley Fool
10:51AM  Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update Zacks
09:25AM  Johnson & Johnson breached its 50 day moving average in a Bearish Manner : JNJ-US : August 9, 2017 Capital Cube
08:20AM  The 3 Best Buffett Stocks for Retirees Motley Fool
07:40AM  Has Johnson & Johnson Been Able to Increase Dividends? Market Realist
Aug-08-17 09:00PM  Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher InvestorPlace
05:56PM  Johnson & Johnson Value Analysis (NYSE:JNJ) : August 8, 2017 Capital Cube
01:59PM  As Drug Overdoses Hit Record High, Trump Offers Little on Opioid Policy Fortune
12:37PM  Why Martin Shkreli Wont Be the Last Pharma Bro Fortune
Aug-07-17 06:10PM  Endo Sets Aside $775 Million to Settle Remaining Mesh Lawsuits Bloomberg
05:04PM  What's Behind TG Therapeutics Inc.'s 14.4% Rally in July? Motley Fool
02:27PM  Why Minerva Neurosciences Inc. Fell 31.1% in July Motley Fool
09:45AM  Q2 Earnings Fail to Impress Pharma ETF Zacks
08:07AM  Beneath the glow of stock-market records, darkly bearish trends are lurking MarketWatch
07:38AM  Imbruvica Could Significantly Drive AbbVies Revenue Growth Market Realist
Aug-06-17 10:37AM  AbbVies new, cheaper hepatitis C drug could launch the drug worlds own Hunger Games MarketWatch
Aug-04-17 05:17PM  Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years Motley Fool
03:35PM  Whats Next for the Healthcare Sector after a Weak July? Market Realist
02:28PM  Johnson & Johnson to Participate in the 2017 Wells Fargo 12th Annual Healthcare Conference PR Newswire
02:17PM  Johnson & Johnson to Participate in Barclays Global Consumer Staples Conference PR Newswire
11:13AM  [$$] CVS Formulary Changes Boost JNJ, Pfizer; Hurt Lilly
10:39AM  Analysts Recommendations for AbbVie in August 2017 Market Realist
08:47AM  Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals Zacks
Aug-03-17 02:41PM  How Avons CEO Failed to Fix the Company Fortune
09:59AM  Three Large Cap Pharma Picks That Can Outperform This Year
08:18AM  Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss Zacks
Aug-02-17 04:28PM  U.S. FDA panel votes against approval of J&J arthritis drug Reuters
03:34PM  U.S. FDA panel votes against approval of J&J arthritis drug Reuters
11:56AM  Jeff Auxier's Summer 2017 Market Commentary
07:39AM  How the YouTube Boycott Affected Alphabets 2Q17 Market Realist
07:35AM  Eli Lillys Valuation after 2Q17 Earnings Release Market Realist
Aug-01-17 11:50PM  5 Super Low-Cost ETFs Kiplinger
06:11PM  Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers
04:26PM  3 Dividend Stocks That Smart Investors Should Own in Bear Markets Motley Fool
02:08PM  Here's Why Geron Corporation Fell as Much as 16.6% Today Motley Fool
01:35PM  Key drug sales push Pfizer profit up 50 percent Associated Press
12:30PM  Stephanie Link: here's what to buy at record highs CNBC
11:35AM  Biotech Stocks Seen Fueled by Next M&A Wave Investopedia
10:32AM  2 Dividend-Growth Stocks That Are Minting Money Motley Fool
10:11AM  Pfizer (PFE) Surpasses Q2 Earnings Estimates, Misses Sales Zacks
09:10AM  Bristol-Myers Squibbs 2Q17 Earnings: Eliquis Market Realist
07:43AM  Analysts Recommendations for Gilead Sciences in July 2017 Market Realist
07:41AM  Bristol-Myers Squibbs 2Q17 Earnings: Virology Products Market Realist
07:29AM  Key FDA Events to Watch Out for in Aug 2017 Zacks
06:25AM  [$$] White hat hackers seek cures for security flaws in medical devices Financial Times
Jul-31-17 09:33PM  3 Dividend Stocks for Retirement Motley Fool
01:00PM  3 Dividend Stocks Perfect for Senior Citizens Motley Fool
10:30AM  Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY Zacks
09:59AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck and Co., McDonald's, Caterpillar and The Boeing Company Zacks
09:56AM  J&J arthritis drug sirukumab raises safety concerns -FDA staff Reuters
08:37AM  J&J arthritis drug sirukumab raises safety concerns - FDA staff Reuters
08:06AM  Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More Zacks
Jul-29-17 08:08AM  Ignore the Obamacare fight in Congress and buy these 5 health-care stocks MarketWatch
Jul-28-17 04:30PM  Celgene Corporation Continues to Get It Done Motley Fool
01:41PM  [$$] Merck Says Cyberattack Hit Production, Will Hurt Profit The Wall Street Journal
11:47AM  Surprise: Those great companies generally turn out to be meh ... or duds MarketWatch
09:53AM  What Big Business Can Teach Entrepreneurs about Purpose Fortune
09:48AM  AbbVie Inc (ABBV) Q2 Beat Fueled by Best Worlds Best-Selling Drug InvestorPlace
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stoffels PaulusExec VP, Chief Scientific OffJul 24Option Exercise72.54102,6927,449,278230,342Jul 26 11:49 AM
Stoffels PaulusExec VP, Chief Scientific OffJul 24Sale133.14102,69213,672,629127,650Jul 26 11:49 AM
Caruso Dominic JExec VP, Finance; CFOJul 20Option Exercise61.7582,5915,099,994226,693Jul 24 11:06 AM
Caruso Dominic JExec VP, Finance; CFOJul 20Sale136.7282,59111,291,478144,102Jul 24 11:06 AM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Option Exercise59.7650,0002,987,780118,536Mar 07 04:21 PM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Sale123.6250,0006,181,14068,536Mar 07 04:21 PM
Kapusta Ronald AController, CAOFeb 28Option Exercise72.5414,5431,054,94944,507Mar 02 05:50 PM
Kapusta Ronald AController, CAOFeb 28Sale122.2614,5431,777,95429,964Mar 02 05:50 PM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 28Sale122.2116,2991,991,94343,630Mar 02 05:16 PM
Stoffels PaulusExec VP, Chief Scientific OffFeb 15Sale117.2922,0002,580,274127,650Feb 16 06:53 PM
Caruso Dominic JExec VP, Finance; CFOFeb 13Option Exercise0.0026,9470150,700Feb 15 10:00 PM
Kapusta Ronald AController, CAOFeb 13Option Exercise0.002,148030,052Feb 16 06:01 AM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 13Option Exercise0.0015,532063,405Feb 16 06:01 AM
Duato JoaquinExec VP, WW Chair, PharmaFeb 13Option Exercise0.0022,298075,814Feb 16 06:01 AM
Fasolo PeterExec VP, Chief HR OfficerFeb 13Option Exercise0.0015,598068,899Feb 16 06:01 AM
Gorsky AlexChairman, CEOFeb 13Option Exercise0.0084,2990280,617Feb 16 06:01 AM
PETERSON SANDRA EExec VP, Group WW ChairmanFeb 13Option Exercise0.0027,667069,436Feb 16 06:01 AM
Stoffels PaulusExec VP, Chief Scientific OffFeb 13Option Exercise0.0026,4470156,125Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 13Option Exercise0.0014,6000114,866Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 01Option Exercise65.6227,7351,819,971119,190Feb 03 12:05 PM
Ullmann Michael HExec VP, General CounselFeb 01Sale112.8821,7352,453,44297,455Feb 03 12:05 PM
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM